Mainstream

Arcturus signals extended cash runway into 2028 with strategic shift toward cf and otc mrna therapeutics

Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics

Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics

Post ContentarctRead More

You might also be interested in reading Gold Keeps Shining on Global Tariff Watch, Surpasses $2,800 Mark.

May 12, 2025
In Mainstream